Antabio
Antabio is a privately-held clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments for drug-resistant infections caused by WHO and CDC critical priority pathogens. The company focuses on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. With an international team of experts and a strong track record of attracting non-dilutive funding, Antabio aims to address urgent unmet medical needs in the antibacterial space.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Intravenous carbapenem plus serine β-lactamase inhibitor combination for severe hospital Gram-negative infections
A β-lactam/β-lactamase inhibitor combination developed to restore carbapenem activity against carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii and other priority Gram-negative pathogens; developed through clinical trials for hospital-acquired infections including nosocomial pneumonia.
Inhaled elastase inhibitor for Pseudomonas aeruginosa respiratory infections
Nebuliser-administered inhaled small-molecule inhibitor targeting Pseudomonas elastase to reduce virulence and support treatment of chronic respiratory infections such as cystic fibrosis, bronchiectasis and COPD.
Metallo-β-lactamase inhibitor to restore carbapenem activity against NDM-producing strains
A small-molecule metallo-β-lactamase inhibitor developed to potentiate carbapenem antibiotics against NDM-positive Enterobacterales and similar resistant pathogens (preclinical and publication-supported program).
MEM-PIL
A next-generation beta-lactam/beta-lactamase inhibitor combination designed to treat multidrug-resistant infections in hospital wards and ICUs.
Pseudomonas Elastase Inhibitor
An inhaled drug targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and persistence, administered via nebuliser as an alternative or adjunct to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory disease.
PEi
Pseudomonas Elastase Inhibitors delivered via inhalation for chronic respiratory diseases.
Intravenous carbapenem plus serine β-lactamase inhibitor combination for severe hospital Gram-negative infections
A β-lactam/β-lactamase inhibitor combination developed to restore carbapenem activity against carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii and other priority Gram-negative pathogens; developed through clinical trials for hospital-acquired infections including nosocomial pneumonia.
Inhaled elastase inhibitor for Pseudomonas aeruginosa respiratory infections
Nebuliser-administered inhaled small-molecule inhibitor targeting Pseudomonas elastase to reduce virulence and support treatment of chronic respiratory infections such as cystic fibrosis, bronchiectasis and COPD.
Metallo-β-lactamase inhibitor to restore carbapenem activity against NDM-producing strains
A small-molecule metallo-β-lactamase inhibitor developed to potentiate carbapenem antibiotics against NDM-positive Enterobacterales and similar resistant pathogens (preclinical and publication-supported program).
MEM-PIL
A next-generation beta-lactam/beta-lactamase inhibitor combination designed to treat multidrug-resistant infections in hospital wards and ICUs.
Pseudomonas Elastase Inhibitor
An inhaled drug targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and persistence, administered via nebuliser as an alternative or adjunct to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory disease.
PEi
Pseudomonas Elastase Inhibitors delivered via inhalation for chronic respiratory diseases.
Expertise Areas
- Antibacterial drug discovery and development
- β-lactamase inhibitor discovery (serine and metallo classes)
- Clinical development of anti-infectives (early-phase)
- Inhalation therapeutics and nebulised delivery
Key Technologies
- Serine β-lactamase inhibition
- Metallo β-lactamase inhibition
- Combination β-lactam + β-lactamase inhibitor therapy
- Inhalation/nebuliser drug delivery
News & Updates
The positive Phase 1 data supports further patient studies of MEM-ANT3310, a novel antibacterial candidate targeting drug-resistant pathogens.
Dr. Erick Lelouche has been appointed as Chairman of the Board of Directors at Antabio.
Led by the AMR Action Fund, the financing will support the clinical development of MEM-ANT3310 up to Phase 2 trials.
The trial for MEM-ANT3310, targeting severe hospital infections, has begun with initial dosing.
Led by Antabio, ARPEGE is funded by the French government to develop strategies against antimicrobial resistance.
Funding to support the development of MEM-ANT3310, a broad-spectrum therapy targeting WHO’s priority pathogens.
The positive Phase 1 data supports further patient studies of MEM-ANT3310, a novel antibacterial candidate targeting drug-resistant pathogens.
Dr. Erick Lelouche has been appointed as Chairman of the Board of Directors at Antabio.
Led by the AMR Action Fund, the financing will support the clinical development of MEM-ANT3310 up to Phase 2 trials.
The trial for MEM-ANT3310, targeting severe hospital infections, has begun with initial dosing.
Led by Antabio, ARPEGE is funded by the French government to develop strategies against antimicrobial resistance.
Funding to support the development of MEM-ANT3310, a broad-spectrum therapy targeting WHO’s priority pathogens.